JP2024534804A5 - - Google Patents
Info
- Publication number
- JP2024534804A5 JP2024534804A5 JP2024510274A JP2024510274A JP2024534804A5 JP 2024534804 A5 JP2024534804 A5 JP 2024534804A5 JP 2024510274 A JP2024510274 A JP 2024510274A JP 2024510274 A JP2024510274 A JP 2024510274A JP 2024534804 A5 JP2024534804 A5 JP 2024534804A5
- Authority
- JP
- Japan
- Prior art keywords
- stereoisomer
- solvate
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210108316 | 2021-08-17 | ||
| KR10-2021-0108316 | 2021-08-17 | ||
| PCT/KR2022/012254 WO2023022497A1 (ko) | 2021-08-17 | 2022-08-17 | Sos1 억제제 및 이의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534804A JP2024534804A (ja) | 2024-09-26 |
| JP2024534804A5 true JP2024534804A5 (https=) | 2025-07-25 |
Family
ID=85239600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024510274A Pending JP2024534804A (ja) | 2021-08-17 | 2022-08-17 | Ｓｏｓ１阻害剤及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240400518A1 (https=) |
| EP (1) | EP4389738A4 (https=) |
| JP (1) | JP2024534804A (https=) |
| KR (1) | KR20230026288A (https=) |
| CN (1) | CN118119600A (https=) |
| AU (1) | AU2022330732A1 (https=) |
| CA (1) | CA3229566A1 (https=) |
| CL (1) | CL2024000342A1 (https=) |
| IL (1) | IL310872A (https=) |
| MX (1) | MX2024002016A (https=) |
| PE (1) | PE20240879A1 (https=) |
| TW (1) | TW202328076A (https=) |
| WO (1) | WO2023022497A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024172631A1 (ko) * | 2023-02-16 | 2024-08-22 | 주식회사 카나프테라퓨틱스 | Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025163050A1 (en) * | 2024-01-31 | 2025-08-07 | Les Laboratoires Servier | New amide derivatives, pharmaceutical compositions containing them and their uses as sos1 inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202602869A (zh) * | 2024-04-10 | 2026-01-16 | 法商施維雅藥廠 | 新醯胺衍生物、包含其之醫藥組合物及其作為sos1抑制劑之用途 |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| KR20260025068A (ko) * | 2024-08-14 | 2026-02-23 | (주) 사이러스테라퓨틱스 | Sos1 억제 활성을 갖는 신규 화합물 |
| CN119431234A (zh) * | 2024-08-19 | 2025-02-14 | 中国药科大学 | 一种苄胺甲酰类化合物及其制备方法与应用 |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2637620A1 (en) * | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| AU2007275221A1 (en) * | 2006-07-20 | 2008-01-24 | Allen J. Borchardt | Benzothiophene inhibitors of RHO kinase |
| WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20110098324A1 (en) * | 2008-06-25 | 2011-04-28 | Brackley Iii James A | Prolyl hydroxylase inhibitors |
| WO2011112186A1 (en) * | 2010-03-10 | 2011-09-15 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| CN102558147B (zh) * | 2010-12-23 | 2014-09-17 | 江苏先声药物研究有限公司 | 化合物、制备方法及应用 |
| AR086113A1 (es) * | 2011-04-30 | 2013-11-20 | Abbott Lab | Isoxazolinas como agentes terapeuticos |
| CA2871237A1 (en) * | 2012-04-24 | 2013-10-31 | Chugai Seiyaku Kabushiki Kaisha | Benzamide derivative |
| WO2014031928A2 (en) * | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| WO2014205594A1 (en) * | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases |
| JP6403172B2 (ja) * | 2013-10-25 | 2018-10-10 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用 |
| HRP20230400T1 (hr) * | 2017-12-21 | 2023-06-23 | Boehringer Ingelheim International Gmbh | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 |
| EP4010333A1 (en) * | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| PH12022551513A1 (en) * | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| IL314594A (en) * | 2022-02-04 | 2024-09-01 | Schr?Dinger Inc | Heterocyclic compounds and methods of use |
-
2022
- 2022-08-17 PE PE2024000267A patent/PE20240879A1/es unknown
- 2022-08-17 JP JP2024510274A patent/JP2024534804A/ja active Pending
- 2022-08-17 IL IL310872A patent/IL310872A/en unknown
- 2022-08-17 CN CN202280069947.0A patent/CN118119600A/zh active Pending
- 2022-08-17 EP EP22858734.1A patent/EP4389738A4/en active Pending
- 2022-08-17 TW TW111130992A patent/TW202328076A/zh unknown
- 2022-08-17 MX MX2024002016A patent/MX2024002016A/es unknown
- 2022-08-17 KR KR1020220102624A patent/KR20230026288A/ko active Pending
- 2022-08-17 WO PCT/KR2022/012254 patent/WO2023022497A1/ko not_active Ceased
- 2022-08-17 AU AU2022330732A patent/AU2022330732A1/en active Pending
- 2022-08-17 US US18/684,629 patent/US20240400518A1/en active Pending
- 2022-08-17 CA CA3229566A patent/CA3229566A1/en active Pending
-
2024
- 2024-02-02 CL CL2024000342A patent/CL2024000342A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024534804A5 (https=) | ||
| JP2024178191A5 (https=) | ||
| AU2008267048B2 (en) | Azapeptide derivatives | |
| JP2022518591A (ja) | 複素環式化合物であるベンゾピリドンおよびその使用 | |
| TW202015698A (zh) | Tlr7/tlr8抑制劑之晶型 | |
| JP2018524333A5 (https=) | ||
| JP2023552610A5 (https=) | ||
| AU2014348523A1 (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| CN114746405A (zh) | 作为反常破坏剂的新braf抑制剂 | |
| CN112135827A (zh) | 盐、晶型及其制备方法 | |
| AU2007220419A1 (en) | Selective androgen receptor modulators | |
| CA2401502A1 (en) | Carboxylic acid derivatives as ip antagonists | |
| JP2021522262A5 (https=) | ||
| JP7370617B2 (ja) | アミノノルカンファン誘導体及びその製造方法と使用 | |
| SG11202110683WA (en) | Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof | |
| WO2017120124A1 (en) | Azetidine modulators of the sphingosine 1-phosphate receptor | |
| CN105026362B (zh) | 双环化合物 | |
| JP2021504464A (ja) | 新規ブラジキニンｂ２受容体アンタゴニスト | |
| CN108778288A (zh) | 可用于治疗疾病的FimH的甘露糖衍生的拮抗剂 | |
| JP2025511277A5 (https=) | ||
| JP2021536505A5 (https=) | ||
| JP2023522725A5 (https=) | ||
| JP2024532249A5 (https=) | ||
| JP2025502712A5 (https=) | ||
| JP2025502497A (ja) | ３－［（ベンゾ［ｄ］［１，３］ジオキソラン－４－イル）オキシ］プロピルアミン塩酸塩およびその光学異性体、結晶、ならびに調製方法 |